Figure 1From: Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients Overall survival of advanced inoperative or postoperative recurrent lung adenocarcinoma patients with skin rash and without skin rash. Back to article page